What development phase is Planipart in?

Planipart is FDA-approved (marketed).

What is the generic name of Planipart?

CLENBUTEROL is the generic (nonproprietary) name of Planipart.

Last reviewed 2026-04-20 · How we verify

Planipart (CLENBUTEROL)

FDA-approved active Small molecule Quality 20/100

At a glance

Generic name	CLENBUTEROL
Drug class	clenbuterol
Target	5-hydroxytryptamine receptor 1A, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Modality	Small molecule
Therapeutic area	Respiratory
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clenbuterol to Target DUX4 in FSHD (PHASE1)
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders (PHASE2)
Response to Clenbuterol in Humans (NA)
Obese Human Beta-2-adrenergic Stimulation and Muscle Glucose Uptake (PHASE2)
A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy (PHASE2)
Muscle Memory After Treatment With Anabolic Substance Clenbuterol and Resistance Training in Humans (NA)
Human Beta-2 Adrenergic Stimulation and Muscle Glucose Uptake (PHASE2)
Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Planipart CI brief — competitive landscape report
Planipart updates RSS · CI watch RSS